FOUNTAIN HILLS, Ariz., Feb. 23, 2011 /PRNewswire/ — Sunridge
International (OTC Bulletin Board/OTCQB: SNDZ), announced today the
signing of an exclusive distribution contract for Turkey.
Based on Turkey’s population of approximately 75 million
people, the 5-year contract with New Amsterdam Marketing
Corporation, should provide a substantial increase in sales.
Preparations are currently being made for Sunridge to send
medical personnel to train local key opinion leaders to assist New
Amsterdam’s marketing rollout.
Sunridge’s CEO, G. Richard Smith stated, “Our goal has always
been to expand our distribution network. With the signing of
this agreement, along with the distribution rights to several
additional countries throughout Europe that we are currently
negotiating, we are very pleased with the progress that we are
making.”
“Recently we expanded our business model to include the addition
of company owned clinics, which is a more aggressive approach for
Sunridge. Our funding efforts for the clinics is progressing
well at this time, and we look forward to advancing into this
highly profitable market.”
Glaucoma is the second leading cause of blindness, affecting
over 70 million people worldwide. PNT has been proven (through
studies completed over the last 10 yrs) to be a safe, effective,
non-invasive and a cost effective alternative for treatment for
glaucoma and ocular hypertension. The 2-minute treatment has been
developed, patented, and distributed by Sunridge International,
wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.CONTACT:Jeff Smith
of Sunridge InternationalT: +1-480-837-6165e-mail:
info@sunridgeint.comMEDIA:Victor Webb of Marston Webb
InternationalT: +1-212-684-6601e-mail:
marwebint@cs.com
‘/>”/>
SOURCE
